Hepion Pharmaceuticals Stock (NASDAQ:HEPA)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$0.50

52W Range

$0.47 - $3.72

50D Avg

$0.64

200D Avg

$1.06

Market Cap

$3.48M

Avg Vol (3M)

$44.21K

Beta

1.81

Div Yield

-

HEPA Company Profile


Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

22

IPO Date

Feb 10, 2014

Website

HEPA Performance


HEPA Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-48.45M$-45.49M$-30.40M
Net Income$-48.93M$-42.20M$-32.72M
EBITDA$-48.45M$-43.54M$-30.32M
Basic EPS$-12.32$-11.07$-9.31
Diluted EPS$-12.32$-11.07$-9.31

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.
OCEAOcean Biomedical, Inc.
ENVBEnveric Biosciences, Inc.